Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Idorsia
Biotech
Eric Topol boards Flagship as advisor—Chutes & Ladders
Eric Topol boards Flagship as advisor. Idorsia CEO hits the exit. Mestag adds $40 million, two new C-suiters.
Darren Incorvaia
,
Zoey Becker
,
Will Maddox
Mar 20, 2026 8:30am
Fierce Pharma
Idorsia shares sink after CEO's abrupt departure
Mar 16, 2026 11:00am
Nxera lays off staff, pivots pipeline in profitability push
Nov 17, 2025 9:44am
Sanofi vaccine vet vaults to GSK—Chutes & Ladders
Jun 13, 2025 8:30am
Nxera sells lupus drug's APAC rights to Viatris for $10M upfront
Feb 28, 2025 5:10am
With no Tryvio buyer, Idorsia recoups $100M from Viatris deal
Feb 26, 2025 7:00am